Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.76 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17815403 | 0.93 | BACE1 (0.79) | BACE1BACE2CYP2D6 | |
| SCHEMBL11917948 | 0.93 | BACE1 (0.79) | BACE1BACE2CYP2D6 | |
| SCHEMBL22990839 | 0.90 | BACE1 (0.79) | BACE1BACE2CYP2D6 | |
| SCHEMBL17815343 | 0.90 | BACE1 (0.79) | BACE1BACE2CYP2D6 | |
| SCHEMBL17815361 | 0.90 | BACE1 (0.79) | BACE1BACE2CYP2D6 | |
| SCHEMBL17815401 | 0.90 | BACE1 (0.79) | BACE1BACE2 | |
| SCHEMBL17815404 | 0.87 | BACE1 (0.69) | BACE1BACE2 | |
| SCHEMBL14788018 | 0.86 | BACE1 (1.00) | BACE1BACE2CYP2D6 | |
| SCHEMBL20005548 | 0.84 | BACE1 (1.00) | BACE1BACE2CYP2D6 | |
| SCHEMBL16709923 | 0.84 | BACE1 (1.00) | BACE1BACE2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656974-B2 | Oxazine derivatives | SHIONOGI & CO., LTD. (JP) | 2017-05-23 | — | — | US | disclosed |
| US-20160159757-A1 | OXAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159757-A1 | OXAZINE DERIVATIVES | APP, BACE1, PSEN1 | BACE1 2/4885BACE2 8/4885CYP2D6 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.